A lthough using embryonic, fetal, and adult brain-derived neural stem cells may be a viable approach for treatment of neurological disease, 1,2 ethical and moral concerns, as well as limited availability, have prompted the search for alternative stem cell sources. Stem cells harvested from bone marrow and cord blood can exhibit neuronal or glial cell properties under defined culture conditions. [3] [4] [5] Moreover, these cells can mediate therapeutic effects in several animal models of neurological diseases, including stroke. 6 -9 Cord blood has emerged as an alternative to bone marrow because of its greater availability, weak immunogenicity, and lower risk of mediating viral transmission. 10 We have reported significant behavioral benefit after intravenous infusion of human umbilical cord blood cells (HUCBC) in the rat middle cerebral artery occlusion (MCAO) model of stroke. 8, 11 Moreover, we demonstrated that intravenous infused HUCBC was comparable to, if not better than, intrastriatally transplanted HUCBC in mediating behavioral recovery after MCAO. 8 Because a specific dose range has not been defined, the present study characterizes the best dose at which intravenously delivered HUCBC mediate neurological recovery and limit brain damage after stroke injury in adult rats.
Materials and Methods

Animals
Adult Sprague Dawley rats (average body weight range, 175.0Ϯ25.0 grams; Harlan, Indianapolis, Ind) were housed in a temperaturecontrolled room with water and chow ad libidum. Rats were randomly assigned to 7 groups: sham surgery (nϭ4), MCAO only (nϭ13), rats infused with 10 4 (nϭ6), 10 5 (nϭ6), 10 6 (nϭ6), 10 7 (nϭ6), or 3 to 5ϫ10 7 (nϭ4) HUCBC 24 hours after MCAO.
MCAO
The rats were anesthetized with isoflurane (2% to 5% in O 2 , at 2 L/min). The right common carotid artery and external carotid artery were exposed and an embolus (4.0 monofilament) was inserted through the external carotid Ϸ25 mm through the internal carotid to the origin of the MCA. The embolus was tied-in permanently. All animal protocols were approved by the Institutional Animal Care and Use Committee at the University of South Florida in accordance with the National Institutes of Health guidelines.
Preparation of HUCBC for Transplantation
The HUCBC were donated for research purposes from a cord blood cell bank (Saneron CCEL Therapeutics, Inc, Tampa, Fla). Cryopreserved HUCBC were rapidly thawed at 37°C and resuspended into Isolyte S, pH 7.4 (BBraun/McGaw Pharmaceuticals). Viability and cell quantification was determined by the trypan-blue dye exclusion method.
Transplantation of HUCBC
The animals were anesthetized with isoflurane and the femoral vein was isolated. Cells were delivered with a 26-gauge Hamilton syringe in a volume of 500 L over 5 minutes. The MCAO-only rats received the HUCBC-free media (Isolyte S). After the infusion, all animals were injected with cyclosporin A daily (10 mg/kg intraperitoneally). Because cyclosporin has neuroprotective activity in MCAO, 12 animals that did not receive HUCBC were also injected daily with cyclosporin A.
Behavioral Measurements
Behavioral tests were performed in all animals before MCAO, and at 2 and 4 weeks after MCAO.
Spontaneous Activity
Spontaneous activity was measured by the automated VersaMax System (Accuscan Instruments, Inc) as previously described. Thirteen locomotor parameters (Table 1) were measured every 5 minutes for 1 hour, and the total activity for each parameter was calculated as the sum of all the 12 measures.
Elevated Body Swing Test
Rats were examined for lateral movements after elevation by their tails to Ϸ10 cm above the surface of the testing area. The frequency 
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of left or right swing was scored over 20 consecutive trials. The bias was calculated as the absolute value of the difference between the number of swings on the impaired side minus 10.
Step Test
Rats were held tightly with one forelimb on a hard flat surface and subsequently pulled for a length of 1 meter in the direction of the placed forelimb. The difference between number of steps performed with the right paw and the left paw was calculated.
Pathological Evaluation
At the conclusion of the behavioral tests, rats were anesthetized with Nembutal (150 mg/kg, intraperitoneally) and perfused transcardially with 0.1 mol/L phosphate buffer, followed by 4% paraformaldehyde.
Brains and other organs (heart, lungs, liver, kidney, spleen, thymus, and bone marrow) were harvested, cryoprotected in a 20% sucrose/ 0.1 mol/L phosphate buffer solution, followed by cryosectioning (20 m). The Nissl-Thionine staining was performed by application of the Nissl-Thionine dye for 50 seconds. The areas of cerebral infarction were delineated at 6 preselected coronal sections (from 1.7 mm anterior to bregma through 3.3 mm posterior to bregma) and quantified using an image analyzer (Image Pro Plus). The total volume of ischemic tissue and that of the contralateral hemisphere were calculated as follows: total volumeϭ⌺[(area of predefined coronal sections mm 2 )] 1-6 ϫ[intersection distance (mm)]. Because at 1 month after MCAO the injured brain hemisphere has typically undergone a shrinkage process, we calculated the volume of ischemic damage as percent of contralateral (intact) hemisphere volume. 13 
Polymerase Chain Reaction Analysis
DNA was obtained from the brain and other organs of half of the animals for each group. Polymerase chain reaction (PCR) was performed for the human glycerol-3-phosphate dehydrogenase (HG3PDH) gene using primers (sense: 5Ј-GGCTGGGACTCATGGAGAT-3Ј; and antisense: 5Ј-CGGGTAAGTCGTTGA-GAAAG-3Ј). Nested PCR was performed with primers (sense: 5Ј-TCTTGGAGAGCTGTGGTGTTG-3Ј; antisense: 5Ј-GTTACCTGAAAGGACTGC-3Ј). Products were resolved on 3.5% polyacrylamide gels and visualized by silver staining.
Immunohistochemistry
Autofluorescence was first quenched using the method of Steele et al, 14 after which the sections were incubated with mouse monoclonal antibody against human nuclei (HuNu; Chemicon, Inc), followed by fluorescein isothiocyanate-conjugated goat antimouse secondary antibody (Alexa Molecular Probes). DAPI staining (Molecular Probes, Eugene, Ore) was performed to visualize nucleated cells. Slides were examined under epifluorescence on an Olympus BX60 microscope.
Statistical Analysis
The behavioral data were analyzed using ANOVA with repeated measures and the Kruskall-Wallis H test was used for post hoc comparisons. Infarct size was analyzed with ANOVA and the Newman-Keuls post hoc test.
Results
HUCBC Dose-Dependent Reduction of MCAO-Associated Asymmetry and Hyperactivity: Spontaneous Activity
For 10 of the 13 analyzed parameters, the overall ANOVA revealed significant differences between the groups (pϽ0.0001 to pϽ0.04). Moreover, on 9 of the 13 variables there were significant interactions between groups and time postinfusion, groups and observational period, and groups, time postinfusion, and observational period (pϽ0.001 to pϽ0.03) ( Table 1) . When significant differences were found in the overall analysis, post hoc comparisons with the Kruskall-Wallis H test were performed (Table 2) .
For the parameters counter-clockwise rotations, horizontal activity, movement time, stereotypy count, stereotypy number, stereotypy time, and vertical movement number differences between the dose groups were examined separately at 2 and 4 weeks after MCAO. On counter-clockwise rotations, at 2 weeks, the animals treated with 10 5 , 10 6 , and 3 to 5ϫ10 7 cells were significantly less active than the media-treated controls (pϭ0.03, pϭ0.005, pϭ0.04, respectively) ( Figure  1A ). At 4 weeks, the 10 7 HUCBC group also became significantly less hyperactive than the stroke-only rats (pϭ0.003) and the groups 10 6 and 3 to 5ϫ10 7 remained significantly less active (pϭ0.008 and pϭ0.02, respectively). Similarly, on horizontal activity, there was a significant reduction of movement in the 10 5 , 10 6 , and 3 to 5ϫ10 7 groups compared with the nonrecipient MCAO rats at 2 weeks (pϭ0.005 for all 3 groups), and at 4 weeks the 10 6 and 10 7 dose groups were significantly less active than the MCAOonly (both pϭ0.05) ( Figure 1B ). On stereotypy number and stereotypy time, there was no significant reduction in activity between media-treated and the HUCB-treated groups. On clockwise rotation, total distance, and vertical activity, there were no interactions between HUCBC dose, time postinfusion, and observational period (ie, 12 test time points) (see right column of Table 1 ).
Figure 1. Total spontaneous activity of 2 representative measures: counter-clockwise rotations (CCR) (A) and horizontal activity (HA) (B). At 2 weeks after transplantation, rats infused with 10
5 to 3 to 5ϫ10 7 HUCBC were significantly less active than MCAO-only animals (*pϽ0.05). Similar results were observed at 4 weeks after transplantation with doses of 10 6 and 10 7 (#pϭ0.05).
Stroke October 2004 Elevated Body Swing Test
Before MCAO, all rats displayed relatively little bias (elevated body swing test Ͻ2). At 2 weeks postinfusion, there was no bias between stroke rats whether they had received HUCBC infusion. However, at 4 weeks, the bias of the animals treated with doses of 10 6 and 3 to 5ϫ10 7 was significantly less than that of MCAO-only rats (pϭ0.005 and pϭ0.04, respectively) ( Figure 2A ).
Step Test
Before MCAO, all rats took the same number of steps with the right and the left paw. Rats that had stroke but received only media infusion displayed an increase in asymmetry (expressed as percent of baseline difference between right and left steps) of Ϸ250% and 200% at 2 and 4 weeks, respectively ( Figure 2B ). Rats infused with the highest doses of HUCBC (10 7 and 3 to 5ϫ10 7 ) showed significantly less asymmetry than the media-treated group. At 2 and 4 weeks, both these groups were performing at prestroke baseline levels.
HUCBC Delivery Reduces the Histological Damage Induced by MCAO
Although in the MCAO-only animals the striatum and cortex presented with a vast tissue loss, the administration of HUCBC 24 hours after MCAO significantly reduced the extent of ischemic brain damage, with the cortex and striatum remaining largely intact ( Figure 3A) . Infarct volume in the stroke group receiving media only (nϭ4) was 33.15Ϯ4.29%, whereas animals of the 10 7 group (nϭ5) showed infarcts involving only 11.46Ϯ4.13% of the hemisphere ( Figure 3B ).
Delivered Cells Were Localized to Spleen and Brain as Determined by PCR and Immunohistochemistry
Human nuclei immunoreactive cells were detected only in the spleen and ipsilateral brain hemisphere of animals injected with 10 6 , 10 7 , and 3 to 5ϫ10 7 cell doses ( Figure 4A ). Here, the immunopositive cells were localized predominately to blood vessels, with few cells being detected in the parenchyma of either spleen or brain. To confirm the organ distribution of HUCBC at 4 weeks after MCAO, PCR analysis using HG3PDH was performed. We found HG3PDH A, Representative brain coronal sections of a stroke media-infused rat (first column) and rat that received a dose of 10 7 cells (second column). Cerebral infarct analysis was determined at 6 predefined areas (third column; schema with number indicating position relative to bregma). In the stroke mediainfused (no HUCBC) animals, the ischemic damage was vast with extensive loss of cells in the ipsilateral striatum and cortex. The administration of 10 7 HUCBC 24 hours after MCA occlusion significantly reduced the ischemic brain damage. B, Percentage of infarct volume in all groups. There was a tendency for increased HUCBC dose to decrease infarct volume, which reached statistical significance at the 10 7 dose (pϽ0.01) and 3 to 5ϫ10 7 (pϽ0.05).
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in spleen and ipsilateral brain hemisphere (injured) of animals infused with high doses (Ͼ10 6 ) of HUCBC ( Figure 4B ). However, in the lower HUCBC dose groups (10 4 and 10 5 ), no HG3PDH was found (data not shown). Similarly, no HG3PDH was detected in the thymus, liver, bone marrow, kidney, or lung at any HUCBC dose ( Figure 4B ; kidney and bone marrow not shown).
Discussion
The results of the present study suggest that mitigation of MCAO-induced deficits depend on the number of HUCBC injected. Specifically, at 4 weeks after HUCBC infusion, the majority of the behavioral measures demonstrated that when 10 6 or more HUCBC were used after permanent MCAO, there was significant recovery in behavioral performance; however, at lower doses (10 4 and 10 5 ), although there was a similar tendency, this did not reach significance. Interestingly, at the highest HUCBC doses used (3 to 5ϫ10 7 ) , there was no further behavioral recovery. Curiously, the 10 7 dose group in the elevated body swing test did not demonstrate any statistical improvement as shown by the spontaneous activity and step test for this group. However, review of individual performance on the elevated body swing test suggested the presence of 2 outliers (Ͼ2.5 SD from mean); when these were excluded from the analysis, there was statistically significant improvement on this test, as well (pϽ0.031).
In addition to behavioral improvements, this is the first report, to our knowledge, in which mononuclear cord blood cells are shown to reduce the ischemic volume, especially at 10 7 HUCB or more cells. A number of studies using the rat MCAO model of stroke have previously described a lack in correlation between improved behavioral test performance and ischemic damage. 15, 16 In our study, the mismatch between behavioral and pathological measures observed in doses of HUCBC that are Ͻ10 7 suggest that these cells are mediating dose-dependent protective mechanisms that are manifest as behavioral improvements at doses equal to 10 6 or as behavioral and brain pathologic recovery at doses Ͼ10 6 . Intravenously delivered HUCBC found in the brain 4 weeks after MCAO were exclusively localized to the ischemic hemisphere. Moreover, immunofluorescent localization of the HUCBC by human nuclei detection suggests that their numbers were small and mostly limited to the cerebrovasculature. The most cogent explanation is that the intravenously injected HUCBC may be following homing signals that attract them to the injured site. In fact, in vitro studies have shown that HUCBC can follow chemotactic cues from brain homogenates of stroke rats, 6, 17 and a number of in vivo studies have described tropism properties by intravenously delivered cells. 18, 19 Besides the ipsilateral hemisphere, we also found HUCBC in the spleen. The function of the spleen as a secondary immune organ suggests it may be a tropic target for HUCBC and as such provides a putative mechanism by which HUCBC might modulate the immune system. Only Ϸ1% of HUCBC is CD34-positive, the putative stem cell population; the major fractions are represented by immature lymphocytes (Ϸ65%) and monocytes (Ϸ30%). 20 Interestingly, spleenderived tolerogenic lymphocytes targeting activated blood vessel segments were shown to attenuate brain damage in rats subjected to MCAO, 21 suggesting that in our study HUCBC infusion could be mediating functional recovery from MCAO at the level of the cerebrovasculature. Further, cord blood mononuclear cells have also been reported to express angio- genic factors such as vascular endothelial growth factor and angiopoietin-1 and 2. 22 After an ischemic insult, a cascade of inflammatory molecular and cellular events takes place and clinical studies have suggested that this acute response affects not only clinical outcomes but also the extent of brain injury. 23 The rat MCAO model recapitulates many of the cellular parameters of brain inflammation seen in stroke. Therefore, HUCBC treatment may influence the cascade of inflammatory/immune events and thereby explain the neurobehavioral and histological benefits observed in this study. The mononuclear fraction of cord blood cells produces large amounts of IL-10, 24 a potent anti-inflammatory cytokine, which may be involved in reducing the poststroke inflammatory response.
Molecular-based mechanisms may include not only immune processes mediated by interleukins but also the involvement of growth/trophic factors. The mononuclear cord blood cells have been shown to express growth factors, such as nerve growth factor, 25 and some investigators have hypothesized the major role of endogenous neuroprotective factors in the HUCB-induced ischemic brain recovery. 26 Regardless of the mechanism of action, the clinical relevance of this HUCBC-based therapeutic option for ischemic stroke is obvious, although additional work is needed before use of HUCBC in the clinical setting. For instance, one major obstacle will be attaining the number of cells needed for clinical benefit in man; our highest rat dose would translate into using the cells derived from Ͼ20 cords for just 1 dose of 10 7 . In vitro expansion of the cells before infusion could resolve this issue.
